The company refused the FDA’s request and will continue shipping its therapy, Elevidys, to Duchenne patients who can still ...

A standoff over Elevidys could have major consequences for Duchenne patients, gene therapy companies and the perception of ...

Part of a class of therapies that boost “orexin” proteins, the drug just scored positive results in a Phase 2 trial. Analysts ...

While Stelara is used in fewer indications than Humira, it commands a large market share in its therapeutic areas, most ...

Overall venture funding, as well as “first financing” rounds, fell significantly in the second quarter, reversing 2025’s fast ...

A meeting held by the FDA Thursday spotlighted debate over black box warnings that have limited use of hormone treatment for ...

Quarterly pharmaceutical sales surpassed $15 billion for the first time as strong performance from J&J's cancer medicines ...

Coartem Baby, which was cleared by health authorities in Switzerland, will fill an important gap in treatment. Novartis plans ...

The cell therapy developer, which raised nearly $500 million in 2023 on the promise of its CAR-T work, has floundered since a ...

The drugmaker will provide, at no profit, doses to treat up to 2 million people in resource-limited countries. Meanwhile, Arvinas' John Houston is retiring from his role leading the biotech.

The death of a 51-year-old man in the study follows two other deaths of Duchenne patients treated with Sarepta’s marketed ...

On a conference call, CEO Doug Ingram said the decision to cut 36% of the company's staff and halt several drug programs was ...